Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of “Moderate Buy” by Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $41.00.

A number of brokerages have commented on ELVN. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. This trade represents a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 48,300 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. This trade represents a 18.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 232,180 shares of company stock worth $6,217,033 in the last quarter. 25.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC purchased a new position in shares of Enliven Therapeutics in the second quarter worth $8,024,000. Candriam S.C.A. grew its stake in Enliven Therapeutics by 46.3% during the third quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock valued at $12,473,000 after acquiring an additional 192,702 shares in the last quarter. HighVista Strategies LLC increased its holdings in Enliven Therapeutics by 83.1% in the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock valued at $5,304,000 after acquiring an additional 117,619 shares during the last quarter. Geode Capital Management LLC increased its holdings in Enliven Therapeutics by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after acquiring an additional 63,580 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in Enliven Therapeutics by 2,029.3% in the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after purchasing an additional 410,034 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $31.15 on Wednesday. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -16.75 and a beta of 0.33. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $31.75. The firm has a fifty day moving average price of $27.85 and a 200-day moving average price of $22.63.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). Equities research analysts expect that Enliven Therapeutics will post -1.95 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.